SCHEMBL3395183

SCHEMBL3395183

Cc1c(CC(=O)O)c2cc(F)ccc2n1Cc1ccccc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 18/20 0.68
PTGDR Q13258 3/20 0.58
MMP1 P03956 1/20 0.54
MMP2 P08253 1/20 0.54
MMP3 P08254 1/20 0.54
MMP9 P14780 1/20 0.54
MMP12 P39900 1/20 0.54
MMP13 P45452 1/20 0.54
MMP14 P50281 1/20 0.54
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6524890 0.92 PTGDR2 (0.61) PTGDR2PTGDRMMP1MMP2MMP3
SCHEMBL6524383 0.89 PTGDR2 (0.59) PTGDR2PTGDRMMP1MMP2MMP3
SCHEMBL1466737 0.84 PTGDR2 (0.94) PTGDR2PTGDR
SCHEMBL1466406 0.81 PTGDR2 (1.00) PTGDR2PTGDR
SCHEMBL3399673 0.81 PTGDR2 (0.50) PTGDR2MMP1MMP2MMP3MMP9
SCHEMBL1783187 0.79 PTGDR2 (0.88) PTGDR2
SCHEMBL1466236 0.78 PTGDR2 (0.76) PTGDR2
SCHEMBL2277554 0.77 PTGDR2 (0.75) PTGDR2
SCHEMBL1194089 0.77 PTGDR2 (0.66) PTGDR2PTGDR
SCHEMBL1465975 0.76 PTGDR2 (0.82) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110060026-A1 Indoles Active on CRTH2 Receptor PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2011-03-10 US disclosed
US-20110060026-A1 Indoles Active on CRTH2 Receptor PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2011-03-10 US disclosed
US-20110060026-A1 Indoles Active on CRTH2 Receptor PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2011-03-10 US disclosed
EP-2245010-A1 INDOLES ACTIVE ON CRTH2 RECEPTOR Pulmagen Therapeutics (Asthma) Limited (GB) 2010-11-03 EP disclosed
WO-2009090399-A1 INDOLES ACTIVE ON CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2009-07-23 WO disclosed
WO-2009090399-A1 INDOLES ACTIVE ON CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060026-A1 Indoles Active on CRTH2 Receptor ARRB1, GPR3, HRH3 PTGDR2 173/4885PTGDR 154/4885MMP1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.